Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):1115–1119. doi: 10.1128/aac.41.5.1115

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

D J Demczar 1, A N Nafziger 1, J S Bertino Jr 1
PMCID: PMC163859  PMID: 9145878

Abstract

Two doses of gentamicin (2 and 7 mg/kg of body weight) were administered to 11 healthy volunteers in a randomized, crossover single-dose study to compare their pharmacokinetics. Doses were infused over 1 h with a syringe infusion pump, and 14 concentrations in sera were obtained over an 8-h period. Concentration in serum versus time data were fitted to a two-compartment pharmacokinetic model. In addition, to mimic the clinical setting, subjects' data were fitted by the Sawchuk-Zaske method. Distributional and postdistributional peak concentrations, along with the last obtained concentration in serum, were utilized to compare the following pharmacokinetic variables: volume of distribution at steady state (Vss), half-life, clearance (CL), and maximum concentration in serum (Cmax). With two-compartment pharmacokinetic fitting, significant differences in distribution half-life (average, 21.8 and 41.6 min [P < or = 0.05]) and gentamicin CL (76.6 +/- 6.6 and 67.2 +/- 4.2 ml/min/1.73 m2 [P < or = 0.001]) were found between traditional-dose and high-dose groups, respectively. When the data for concentrations in sera were fitted to a one-compartment pharmacokinetic model by using either the distributional or the postdistributional Cmax, statistically significant differences (P < or = 0.001) were found between Vss, half-life, CL, and Cmax values for both dosage groups. The results show that the pharmacokinetics of gentamicin at a large dose differ significantly from those at the traditional dose. This information has direct implications for once-daily aminoglycoside (ODA) literature when the Cmax values reported are distributional and therefore show falsely high Cmax/MIC ratio estimates. In addition, ODA nomogram dosing tools developed with distributional Cmax values are probably inaccurate.

Full Text

The Full Text of this article is available as a PDF (289.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaser J., König C., Simmen H. P., Thurnheer U. Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother. 1994 Feb;33(2):341–348. doi: 10.1093/jac/33.2.341. [DOI] [PubMed] [Google Scholar]
  2. Franck K. R., Bertino J. S., Jr KINI: a one compartment intravenous pharmacokinetic analysis program. Comput Methods Programs Biomed. 1994 Mar;42(3):157–165. doi: 10.1016/0169-2607(94)90126-0. [DOI] [PubMed] [Google Scholar]
  3. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Konrad F., Wagner R., Neumeister B., Rommel H., Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med. 1993;19(4):215–220. doi: 10.1007/BF01694773. [DOI] [PubMed] [Google Scholar]
  5. Lin C. C., Radwanski E., Korduba C., Cayen M., Affrime M. Pharmacokinetics of intravenously administered isepamicin in men. Antimicrob Agents Chemother. 1995 Dec;39(12):2774–2778. doi: 10.1128/aac.39.12.2774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Maller R., Emanuelsson B. M., Isaksson B., Nilsson L. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis. 1990;22(5):575–579. doi: 10.3109/00365549009027099. [DOI] [PubMed] [Google Scholar]
  7. Meunier F., Van der Auwera P., Schmitt H., de Maertelaer V., Klastersky J. Pharmacokinetics of gentamicin after i.v. infusion or iv bolus. J Antimicrob Chemother. 1987 Feb;19(2):225–231. doi: 10.1093/jac/19.2.225. [DOI] [PubMed] [Google Scholar]
  8. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  9. Nicolau D. P., Freeman C. D., Belliveau P. P., Nightingale C. H., Ross J. W., Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650–655. doi: 10.1128/AAC.39.3.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Parker S. E., Davey P. G. Practicalities of once-daily aminoglycoside dosing. J Antimicrob Chemother. 1993 Jan;31(1):4–8. doi: 10.1093/jac/31.1.4. [DOI] [PubMed] [Google Scholar]
  11. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar]
  12. Sangha K. S., Miyagawa C. I., Healy D. P., Bjornson H. S. Pharmacokinetics of once-daily dosing of gentamicin in surgical intensive care unit patients with open fractures. Ann Pharmacother. 1995 Feb;29(2):117–119. doi: 10.1177/106002809502900201. [DOI] [PubMed] [Google Scholar]
  13. Tanswell P., Koup J. TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program. Int J Clin Pharmacol Ther Toxicol. 1993 Oct;31(10):514–520. [PubMed] [Google Scholar]
  14. Traynor A. M., Nafziger A. N., Bertino J. S., Jr Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995 Feb;39(2):545–548. doi: 10.1128/aac.39.2.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tulkens P. M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother. 1991 May;27 (Suppl 100):49–61. doi: 10.1093/jac/27.suppl_c.49. [DOI] [PubMed] [Google Scholar]
  16. Van der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin. J Antimicrob Chemother. 1991 May;27 (Suppl 100):63–71. doi: 10.1093/jac/27.suppl_c.63. [DOI] [PubMed] [Google Scholar]
  17. Vanhaeverbeek M., Siska G., Herchuelz A. Pharmacokinetics of once-daily amikacin in elderly patients. J Antimicrob Chemother. 1993 Jan;31(1):185–187. doi: 10.1093/jac/31.1.185. [DOI] [PubMed] [Google Scholar]
  18. Verpooten G. A., Giuliano R. A., Verbist L., Eestermans G., De Broe M. E. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989 Jan;45(1):22–27. doi: 10.1038/clpt.1989.4. [DOI] [PubMed] [Google Scholar]
  19. Wagner J. G., Metzler C. M. Prediction of blood levels after multiple doses from single-dose blood level data: data generated with two-compartment open model analyzed according to the one-compartment open model. J Pharm Sci. 1969 Jan;58(1):87–92. doi: 10.1002/jps.2600580118. [DOI] [PubMed] [Google Scholar]
  20. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES